Is Enlivex Ltd. (ENLV) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 8.7% / 30% | 0.5% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 8.7% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| MSCI | 1.9% / 33% | 84.9% / 33% | 5.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 8.7% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| FTSE | 1.9% / 33% | 84.9% / 33% | 5.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | 126.2% | |
| Return on Assets (ROA) | -0.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Total Debt | $534,000 |
| Debt-to-Equity | 0.0 |
| Current Ratio | 193.2 |
| Total Assets | $28M |
Price & Trading
| Last Close | $1.09 |
| 50-Day MA | $1.10 |
| 200-Day MA | $1.09 |
| Avg Volume | 353K |
|
52-Week Range
$0.66
| |
About Enlivex Ltd. (ENLV)
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Enlivex Ltd. (ENLV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Enlivex Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Enlivex Ltd.'s debt ratio?
Enlivex Ltd.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.9%.
What are Enlivex Ltd.'s key financial metrics?
Enlivex Ltd. has a market capitalization of $250M, trailing P/E ratio of 0.0. Return on equity stands at 126.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.